Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Cosan im Q3 2025 mit Nettoverlust – Aktie unter Druck (Investing.com DE) +++ COSAN Aktie +3,49%

ACTINIUM Aktie

 >ACTINIUM Aktienkurs 
1.24 EUR    +12.5%    (Tradegate)
Ask: 1.324 EUR / 2300 Stück
Bid: 1.29 EUR / 2400 Stück
Tagesumsatz: 1022 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ACTINIUM Aktie über LYNX handeln
>ACTINIUM Performance
1 Woche: +3,2%
1 Monat: -17,6%
3 Monate: -19,2%
6 Monate: -16,6%
1 Jahr: -32,6%
laufendes Jahr: -3,4%
>ACTINIUM Aktie
Name:  ACTINIUM PHARMAC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00507W2061 / A2QA48
Symbol/ Ticker:  7AY1 (Frankfurt)
Kürzel:  FRA:7AY1, ETR:7AY1, 7AY1:GR
Index:  -
Webseite:  https://www.actiniumpharm..
Profil:  Actinium Pharmaceuticals Inc. is a clinical-stage ..
>Volltext..
Marktkapitalisierung:  33.56 Mio. EUR
Unternehmenswert:  -16.27 Mio. EUR
Umsatz:  -
EBITDA:  -37.38 Mio. EUR
Nettogewinn:  -35.31 Mio. EUR
Gewinn je Aktie:  -1.13 EUR
Schulden:  1.11 Mio. EUR
Liquide Mittel:  51.57 Mio. EUR
Operativer Cashflow:  -26.41 Mio. EUR
Bargeldquote:  7.21
Umsatzwachstum:  -100%
Gewinnwachstum:  12.46%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ACTINIUM
Letzte Datenerhebung:  17.11.25
>ACTINIUM Kennzahlen
Aktien/ Unternehmen:
Aktien: 31.2 Mio. St.
Frei handelbar: 96.88%
Leerverk. Aktien: -
Rückkaufquote: -11.8%
Mitarbeiter: 37
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 267.7%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 2.6
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -53.68%
Eigenkaprendite: -130.59%
>ACTINIUM Peer Group

Es sind 599 Aktien bekannt.
 
17.11.25 - 14:42
 Econ Corp Services DBA Investorideas.com: The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals′ (ATNM) Big Bet (Newsfile)
 
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking a......
04.11.25 - 13:33
 Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications (PR Newswire)
 
- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab - ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cancer (NSCLC),......
03.11.25 - 14:36
 Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference (PR Newswire)
 
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be participating in the Stephens......
27.10.25 - 12:03
 Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on (PR Newswire)
 
- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT®) - Combination of......
24.10.25 - 14:33
 Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
 
- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology with continued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling potent activity independent of PSMA expression - ATNM-400 demonstrated superior efficacy......
13.10.25 - 18:12
 Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
 
ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally New preclinical findings demonstrate ATNM-400 overcomes resistance to the EGFR inhibitor osimertinib in......
13.10.25 - 14:33
 Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
 
- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression levels - Extended follow-up in prostate cancer models demonstrated durable anti-tumor......
11.09.25 - 14:09
 Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 (GlobeNewswire EN)
 
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors...
03.09.25 - 14:09
 Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire EN)
 
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company's novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma....
02.09.25 - 17:30
 Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
 
Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year....
31.07.25 - 14:33
 Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in (PR Newswire)
 
- ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto® and enzalutamide, follow-up continues - ATNM-400 significantly improved survival compared to the approved prostate cancer treatment Pluvicto®, the first blockbuster radiotherapy -......
26.06.25 - 14:09
 Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement (GlobeNewswire EN)
 
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225...
23.06.25 - 17:33
 Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & (PR Newswire)
 
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ATNM-400 is more efficacious than both Pluvicto® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted......
20.06.25 - 14:03
 Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics (PR Newswire)
 
BOSTON and BELLEVUE, Wash., June 20, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a......
20.06.25 - 13:36
 IONETIX Corporation and AlfaRim Medical B.V. announce a strategic partnership to fast-track commercial production of Actinium-225 (PR Newswire)
 
LANSING, Mich. and DELFT, Netherlands, June 20, 2025 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator and full-service isotope manufacturer, and AlfaRim, a Dutch deeptech company pioneering industrial-scale production of cGMP-grade Actinium-225, today announced a......
17.06.25 - 14:03
 Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals (PR Newswire)
 
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio's clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies' manufacturing and supply chain......
10.06.25 - 17:39
 Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm (PR Newswire)
 
NEW YORK, June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,......
26.05.25 - 14:36
 ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important......
23.05.25 - 11:45
 Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky (PR Newswire)
 
NEW YORK, May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were......
22.05.25 - 16:30
 ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Actinium between October 31, 2022 and August 2, 2024......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Gesetze, Zeiten, Völker überleben sich. Nur die Sternbilder der Kunst schimmern in alter Unvergänglichkeit über den Kirchhöfen der Zeit. - Jean Paul
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!